Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb 2Q

Revenues up 7% in the quarter driven by Hep C franchise

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb
 
2Q Revenues: $4.2 billion (+7%)

2Q Loss: $130 million (earnings were $330 million 2Q14)

FY Revenues: $8.2 billion (+7%)

FY Earnings: $1.1 billion (-17%)

Comments: Hepatitis C Franchise revenues were $479 million in the quarter driven by Daclatasvir. Sprycel sales were up 10% to $405 million. Orencia sales were up 15% to $461 million. Eliquis sales were $437 million compared to $171 in 2Q14. Baraclude sales were down 7% to $343 million; the Reyataz Franchise dropped 16% to $303 million; the Sustiva Franchise was down 12% to $317 million; and Abilify sales dropped 81% to $107 million, due to generic competition. U.S. revenues decreased 3% to $1.8 billion in the quarter. International revenues increased 17%. R&D expenses increased 31% to $1.9 billion in the quarter, primarily due to the acquisition of Flexus Biosciences, Inc.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters